Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de terapia combinada de amivantamab y lazertinib versus osimertinib en cáncer de pulmón de células no pequeñas localmente avanzado o metastásico (MARIPOSA)

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio aleatorizado de fase 3 de la terapia combinada de amivantamab y lazertinib frente a osimertinib frente a lazertinib como tratamiento de primera línea en pacientes con cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con mutación de EGFR.

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

1074

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Bad Berka, Alemania, 99437
        • Zentralklinik Bad Berka GmbH
      • Berlin, Alemania, 14165
        • Helios Klinikum Emil von Behring GmbH
      • Cologne, Alemania, 51109
        • Kliniken der Stadt Koeln gGmbH
      • Essen, Alemania, 45147
        • Universitaetsklinikum Essen
      • Gauting, Alemania, 82131
        • Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
      • Halle, Alemania, 06120
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Heidelberg, Alemania, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Heilbronn, Alemania, 74072
        • Onkologische Schwerpunktpraxis
      • Leipzig, Alemania, 04357
        • POIS Leipzig GbR
      • Oldenburg, Alemania, 26121
        • Pius-Hospital Oldenburg
      • Stuttgart, Alemania, 70376
        • Robert-Bosch-Krankenhaus - Klinik Schillerhoehe
      • Buenos Aires, Argentina, C1428ANZ
        • Instituto Alexander Fleming
      • Buenos Aires, Argentina, C1426AGE
        • Centro Oncológico Korben
      • Córdoba, Argentina, X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • La Rioja, Argentina, F5300COE
        • Centro Oncologico Riojano Integral (Cori)
      • Viedma, Argentina, R8500ACE
        • Clínica Viedma
      • Bedford Park, Australia, 5042
        • Flinders Medical Centre
      • Heidelberg, Australia, 3084
        • Austin Hospital
      • Malvern, Australia, 3144
        • Cabrini Medical Centre
      • Murdoch, Australia, 6150
        • St John of God Hospital Murdoch
      • Nedlands, Australia, 6009
        • Sir Charles Gairdner Hospital
      • Westmead, Australia, 2145
        • Westmead Hospital
      • Wollongong, Australia, 2500
        • Southern Medical Day Care Centre
      • Woolloongabba, Australia, 4102
        • Princess Alexandra Hospital
      • Barretos, Brasil, 14784-400
        • Fundacao Pio XII
      • Belo Horizonte, Brasil, 30110-022
        • Cetus Oncologia
      • Florianópolis, Brasil, 88020-210
        • Ynova Pesquisa Clinica
      • Ijuí, Brasil, 98700-000
        • Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
      • Natal, Brasil, 59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Pelotas, Brasil, 96020 080
        • UPCO Unidade de Pesquisa Clinica em Oncologia
      • Porto Alegre, Brasil, 90020-090
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasil, 90610-000
        • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
      • Rio de Janeiro, Brasil, 22 250 905
        • Oncoclinicas Rio de Janeiro S A
      • Rio de Janeiro, Brasil, 20231 050
        • Ministerio da Saude Instituto Nacional do Cancer
      • Rio de Janeiro, Brasil, 22281 100
        • IDOR - Regional Rio de Janeiro
      • Sorocaba, Brasil, 18030-075
        • IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
      • São Paulo, Brasil, 04014-002
        • Núcleo de Pesquisa São Camilo
      • São Paulo, Brasil, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasil, 01246 000
        • Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
      • Vitória, Brasil, 29308-014
        • Hospital Evangélico de Cachoeiro de Itapemirim
      • Brussels, Bélgica, 1200
        • Cliniques Universitaires Saint Luc
      • Charleroi, Bélgica, 6060
        • Grand Hopital De Charleroi Site Les Viviers
      • Leuven, Bélgica, 3000
        • UZ Leuven
      • Ottignies, Bélgica, 1340
        • Clinique Saint Pierre
      • Roeselare, Bélgica, 8800
        • Algemeen Ziekenhuis Delta
    • Ontario
      • Brampton, Ontario, Canadá, L6R 3J7
        • William Osler Health System
      • Hamilton, Ontario, Canadá, L8V 5C2
        • Juravinski Cancer Centre
      • Ottawa, Ontario, Canadá, K1H 8L6
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Montreal, Quebec, Canadá, H4A 3J1
        • McGill University Health Centre
      • Busan, Corea del Sur, 48108
        • Inje University Haeundae Paik Hospital
      • Cheongju-si, Corea del Sur, 28644
        • Chungbuk National University Hospital
      • Seongnam-si, Corea del Sur, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Corea del Sur, 05505
        • Asan Medical Center
      • Seoul, Corea del Sur, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Corea del Sur, 06351
        • Samsung Medical Center
      • Seoul, Corea del Sur, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Corea del Sur, 06591
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Seoul, Corea del Sur, 8308
        • Korea University Guro Hospital
      • A Coruña, España, 15006
        • Hosp Univ A Coruna
      • Badalona, España, 08916
        • Inst. Cat. D'Oncologia-Badalona
      • Barcelona, España, 08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, España, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, España, 08035
        • Hosp Univ Vall D Hebron
      • Burgos, España, 09003
        • Hosp. Univ. de Burgos
      • Girona, España, 17007
        • Institut Català D'Oncologia Girona
      • Madrid, España, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, España, 28046
        • Hosp. Univ. La Paz
      • Madrid, España, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Majadahonda, España, 28222
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Málaga, España, 29011
        • Hosp Regional Univ de Malaga
      • Pamplona, España, 31008
        • Clinica Univ. de Navarra
      • Seville, España, 41013
        • Hosp. Virgen Del Rocio
      • Valencia, España, 46014
        • Hosp. Gral. Univ. Valencia
      • Zaragoza, España, 50009
        • Hosp. Clinico Univ. Lozano Blesa
    • Arizona
      • Goodyear, Arizona, Estados Unidos, 85395
        • Arizona Oncology Associates, PC - HAL
      • Yuma, Arizona, Estados Unidos, 85364
        • Yuma Regional Medical Center
    • California
      • Long Beach, California, Estados Unidos, 90813
        • City of Hope Long Beach Elm
      • Orange, California, Estados Unidos, 92868
        • University of California Irvine
    • Colorado
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Rocky Mountain Cancer Centers
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Cancer Specialists of North Florida
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
        • University Cancer And Blood Center LLC
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
        • East Jefferson General Hospital
    • Maryland
      • Columbia, Maryland, Estados Unidos, 21044
        • Maryland Oncology Hematology, PA
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Hospital
    • Minnesota
      • Edina, Minnesota, Estados Unidos, 55435
        • Minnesota Oncology Hematology P A
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School Of Medicine
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816
        • Astera Cancer Care
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Willamette Valley Cancer Institute and Research Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Austin, Texas, Estados Unidos, 78745
        • Texas Oncology P A
      • Houston, Texas, Estados Unidos, 77030
        • Oncology Consultants Texas
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Virginia Cancer Specialists
      • Bordeaux, Francia, 33000
        • Institut Bergonie
      • Bron, Francia, 69500
        • Hospices Civils de Lyon HCL
      • La Tronche, Francia, 38700
        • CHU de Grenoble Hopital Albert Michallon
      • Lille, Francia, 59000
        • Institute Coeur Poumon
      • Limoges, Francia, 87000
        • CHU de Limoges
      • Marseille, Francia, 13915
        • Hopital Nord
      • Paris, Francia, 75005
        • Institut Curie
      • Paris, Francia, 75970
        • Hopital Tenon
      • Pessac, Francia, 33604
        • CHU Bordeaux
      • Sain-Herblain, Francia, 44800
        • CHU Nantes
      • Saint-Mandé, Francia, 94163
        • HIA Begin
      • Tours, Francia, 37000
        • CHU Bretonneau
      • Villejuif, Francia, 94805
        • Institut Gustave Roussy
      • Budapest, Hungría, H-1529
        • Orszagos Koranyi Tbc es Pulmonologiai Intezet
      • Farkasgyepü, Hungría, 8582
        • Veszprém Megyei Tudőgyógyintézet
      • Gyöngyös, Hungría, 3233
        • Mátrai Gyógyintézet-Bronchológia
      • Szombathely, Hungría, 9700
        • Markusovszky Egyetemi Oktatokorhaz
      • Székesfehérvár, Hungría, 8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Törökbálint, Hungría, 2045
        • Tudogyogyintezet Torokbalint
      • Hyderabad, India, 500034
        • Basavatarakam Indo-American Hospital
      • Kolkata, India, 700160
        • Tata Medical Center
      • Mumbai, India, 400012
        • Tata Memorial Hospital
      • Nashik, India, 422002
        • HCG Manavta Cancer Centre
      • Pune, India, 411013
        • Noble Hospital Pvt Ltd
      • Haifa, Israel, 3109601
        • Rambam Health Corporation
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center
      • Kfar Saba, Israel, 44281
        • Meir Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center
      • Ramat Gan, Israel, 5262100
        • Chaim Sheba Medical Center
      • Tel Aviv, Israel, 6423906
        • Tel Aviv Sourasky Medical Center
      • Avellino, Italia, 83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Catania, Italia, 95123
        • Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
      • Meldola, Italia, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
      • Milan, Italia, 20141
        • Istituto Europeo di Oncologia
      • Milan, Italia, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Italia, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, Italia, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Monza, Italia, 20052
        • San Gerardo Hospital
      • Naples, Italia, 80100
        • Ospedale Monaldi
      • Orbassano, Italia, 10043
        • Aou San Luigi Gonzaga
      • Ravenna, Italia, 48121
        • Ospedale S. Maria Delle Croci
      • Roma, Italia, 00168
        • Irccs Gemelli
      • Rozzano, Italia, 20089
        • Istituto Clinico Humanitas
      • Bunkyō City, Japón, 113 8431
        • Juntendo University Hospital
      • Chūōku, Japón, 104 0045
        • National Cancer Center Hospital
      • Fukuoka, Japón, 810-8563
        • National Hospital Organization Kyushu Medical Center
      • Himeji, Japón, 670-8520
        • National Hospital Organization Himeji Medical Center
      • Hirakata, Japón, 573 1191
        • Kansai Medical University Hospital
      • Kanazawa, Japón, 920 8641
        • Kanazawa University Hospital
      • Kashiwa, Japón, 277 8577
        • National Cancer Center Hospital East
      • Kurume, Japón, 830-0011
        • Kurume University Hospital
      • Matsusaka, Japón, 515-8544
        • Matsusaka Municipal Hospital
      • Niigata, Japón, 951-8566
        • Niigata Cancer Center Hospital
      • Okayama, Japón, 700 8558
        • Okayama University Hospital
      • Osaka Sayama Shi, Japón, 589 8511
        • Kindai University Hospital
      • Shibukawa, Japón, 377-0280
        • National Hospital Organization Shibukawa Medical Center
      • Tokyo, Japón, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Tokyo, Japón, 152 8902
        • National Hospital Organization Tokyo Medical Center
      • Toon-shi, Japón, 791-0295
        • Ehime University Hospital
      • Toyonaka-shi, Japón, 560-8552
        • National Hospital Organization Osaka Toneyama Medical Center
      • Wakayama, Japón, 641 8510
        • Wakayama Medical University Hospital
      • Yamaguchi, Japón, 740-8510
        • National Hospital Organization Iwakuni Clinical Center
      • Yamaguchi, Japón, 755-0241
        • National Hospital Organization Yamaguchi Ube Medical Center
      • George Town, Malasia, 10990
        • Hospital Pulau Pinang
      • Johor Bahru, Malasia, 81100
        • Hospital Sultan Ismail
      • Kuala Lumpur, Malasia, 50586
        • Hospital Kuala Lumpur
      • Kuala Lumpur, Malasia, 59100
        • University Malaya Medical Centre
      • Kuantan, Malasia, 25100
        • Hospital Tengku Ampuan Afzan
      • Petaling Jaya, Malasia, 46050
        • Beacon Hospital Sdn Bhd
      • Guadalajara, México, 44280
        • Hospital Civil de Guadalajara Fray Antonio Alcalde
      • León, México, 37000
        • CIMOVA, Morals Vargas Centro de Investigación SC
      • Mexico City, México, 14050
        • Médica Sur
      • Mexico City, México, 03100
        • Mexico Centre for Clinical Research, S.A. de C.V.
      • Monterrey, México, 64710
        • i Can Oncology Center
      • México, México, 14080
        • Instituto Nacional de Cancerologia
      • México, México, 03100
        • Health Pharma Professional Research
      • Naucalpan, México, 53100
        • Oncologia Integral Satelite
      • 's-Hertogenbosch, Países Bajos, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Arnhem, Países Bajos, 6815 AD
        • Rijnstate Ziekenhuis
      • Harderwijk, Países Bajos, 3844 DG
        • Ziekenhuis St Jansdal
      • Nijmegen, Países Bajos, 6525AG
        • UMC Radboud
      • Bydgoszcz, Polonia, 85 796
        • Centrum Onkologii im Prof F Lukaszczyka
      • Gdansk, Polonia, 80 214
        • Uniwersyteckie Centrum Kliniczne
      • Gdynia, Polonia, 81 519
        • Szpitale Pomorskie Sp z o o
      • Olsztyn, Polonia, 10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
      • Poznan, Polonia, 60-693
        • Private Specialist Hospitals - MedPolonia
      • Warsaw, Polonia, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Beijing, Porcelana, 100853
        • Chinese PLA General Hospital
      • Beijing, Porcelana, 100050
        • Beijing Friendship Hospital Capital Medical University
      • Beijing, Porcelana, 100142
        • Beijing Cancer Hospital Respiratory Medicine Department II
      • Beijing, Porcelana, 100142
        • Beijing Cancer Hospital Respiratory Medicine Department I
      • Beijing, Porcelana, 101149
        • Beijing Chest hospital, Capital medical university
      • Changchun, Porcelana, 130000
        • Jilin cancer hospital
      • Changsha, Porcelana, 410013
        • Hunan Cancer hospital Thoracic Medicine Department II
      • Changsha, Porcelana, 410013
        • Hunan Cancer hospital Thoracic Medicine Department I
      • Changzhou, Porcelana, 213003
        • The First People's Hospital Of Changzhou
      • Chengdu, Porcelana, 610041
        • Sichuan Cancer Hospital
      • Chengdu, Porcelana, 610041
        • West China Hospital Sichuan University
      • Chongqing, Porcelana, 400038
        • Southwest Hospital
      • Guangzhou, Porcelana, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Guangzhou, Porcelana, 510120
        • Sun Yat-Sen Memorial Hospital Sun Yat-sen University
      • Hangzhou, Porcelana, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Porcelana, 310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
      • Hangzhou, Porcelana, 310009
        • The Second Affiliated Hospital of Zhejiang University College of Medicine
      • Hangzhou, Porcelana, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Harbin, Porcelana, 150000
        • Harbin medical university cancer hospital
      • Huizhou, Porcelana, 516001
        • Huizhou Municipal Central Hospital
      • Linhai, Porcelana, 317000
        • Taizhou Hospital of Zhejiang Province
      • Nantong, Porcelana, 226300
        • Nantong Tumor Hospital
      • Shanghai, Porcelana, 200030
        • Shanghai Chest Hospital
      • Shanghai, Porcelana, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Porcelana, 200123
        • Shanghai East Hospital
      • Shanghai, Porcelana, 200025
        • Ruijin Hospital Shanghai Jiao Tong University
      • Shenyang, Porcelana, 110004
        • Shengjing Hospital Of China Medical University
      • Tianjin, Porcelana, 300052
        • Tianjin Medical University General Hospital
      • Wenzhou, Porcelana, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Porcelana, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an, Porcelana, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Yantai, Porcelana, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, Porcelana, 450008
        • Henan Cancer Hospital
      • Ürümqi, Porcelana, 830000
        • Cancer Hospital of Xinjiang Medical University
      • Lisbon, Portugal, 1769-001
        • Uls Santa Maria - Hosp. Pulido Valente
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia
      • Porto, Portugal, 4099-001
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Porto, Portugal, 4100 180
        • Hosp. Cuf Porto
      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials LLC
      • Edinburgh, Reino Unido, EH4 2XU
        • Edinburgh Cancer Centre Western General
      • London, Reino Unido, NW1 2PG
        • UCL Cancer Institute
      • London, Reino Unido, SW3 6JJ
        • The Royal Marsden NHS Trust
      • London, Reino Unido, SW10 9NH
        • Chelsea And Westminster Hospital
      • Manchester, Reino Unido, M20 4BX
        • Christie NHS Foundation Trust
      • Nottingham, Reino Unido, NG5 1PB
        • Nottingham University Hospitals NHS Trust
      • Sutton, Reino Unido, SM2 5PT
        • The Royal Marsden NHS Trust 1
      • Irkutsk, Rusia, 664035
        • Irkutsk Regional Oncology Dispensary
      • Krasnoyarsk, Rusia, 660133
        • Krasnoyarsk Regional Oncology Dispensary
      • Kuzmolovsky, Rusia, 188663
        • Leningrad Regional Oncology Dispensary
      • Moscow, Rusia, 115533
        • MCK
      • Moscow, Rusia, 121205
        • Moscow City Oncology Hospital No 62
      • Nal'chik, Rusia, 360000
        • City Clinical Hospital #1
      • Nizhny Novgorod, Rusia, 603000
        • Nizhny Novgorod Regional Oncological Dispensary
      • Omsk, Rusia, 664013
        • Omsk Clinical Oncology Dispensary
      • Saint Petersburg, Rusia, 197758
        • N.N. Petrov Research Institute Of Oncology
      • Saint Petersburg, Rusia, 196006
        • Oncology Medical Clinics AV Medical group
      • Saint Petersburg, Rusia, 190121
        • Current medical technologies
      • Tambov, Rusia, 392013
        • Tambov Regional Oncology Clinical Dispansary
      • Tomsk, Rusia, 634050
        • Tomsk Cancer Research Institute
      • Ufa, Rusia, 450083
        • Bashkir State Medical University
      • Yaroslavl, Rusia, 150054
        • Yaroslavl Regional Clinical Oncology Hospital
      • Bangkok, Tailandia, 10700
        • Siriraj Hospital
      • Bangkok, Tailandia, 10400
        • Phramongkutklao Hospital and Medical College
      • Chiang Mai, Tailandia, 50200
        • Chiang Mai University
      • Songkhla, Tailandia, 90110
        • Songklanagarind Hospital, Prince of Songkla University
      • Kaohsiung City, Taiwán, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Kaohsiung City, Taiwán, 833
        • Chang Gung Medical Foundation
      • Kaohsiung City, Taiwán, 824
        • E-DA Hospital
      • New Taipei City, Taiwán, 23561
        • Taipei Medical University Shuang Ho Hospital
      • Taichung, Taiwán, 40447
        • China Medical University Hospital
      • Taichung, Taiwán, 402
        • Chung Shan Medical University Hospital
      • Tainan, Taiwán, 704
        • National Cheng Kung University Hospital
      • Taipei, Taiwán, 10002
        • National Taiwan University Hospital
      • Adana, Turquía (Türkiye), 01060
        • Adana City Hospital
      • Adana, Turquía (Türkiye), 01250
        • Başkent University Medical Faculty Adana Application and Research Center
      • Ankara, Turquía (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Ankara, Turquía (Türkiye), 06560
        • Gazi Hastanesi
      • Edirne, Turquía (Türkiye), 22030
        • Trakya University Medical Faculty
      • Istanbul, Turquía (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
      • Istanbul, Turquía (Türkiye), 34722
        • T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
      • Istanbul, Turquía (Türkiye), 34214
        • Medipol Mega University Hospital
      • Izmir, Turquía (Türkiye), 35575
        • Medical Point
      • Konya, Turquía (Türkiye), 42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Dnipro, Ucrania, 49102
        • Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
      • Kharkiv, Ucrania, 61070
        • Municipal non-profit enterprise 'Regional Center of Oncology'
      • Kyiv, Ucrania, 02091
        • Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
      • Kyiv, Ucrania, 03022
        • State Nonprofit Enterprise National Cancer Institute
      • Uzhhorod, Ucrania, 88000
        • Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
  • The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
  • Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis)
  • Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
  • Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy

Exclusion Criteria:

  • Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid treatment or receiving low-dose corticosteroid treatment less than or equal to (<=) 10 milligrams per day (mg/day) prednisone or equivalent
  • Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
  • Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib
  • Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment Arm A (Open-label): Amivantamab and Lazertinib

Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.

Participants will receive amivantamab intravenously.

Otros nombres:
  • JNJ-61186372

Participants will receive lazertinib tablets orally.

Otros nombres:
  • JNJ-73841937 y YH-25448
Comparador activo: Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib

Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.

Participants will receive osimertinib capsules orally.

Participants will receive matching placebo orally.

Experimental: Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib

Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.

Participants will receive lazertinib tablets orally.

Otros nombres:
  • JNJ-73841937 y YH-25448

Participants will receive matching placebo orally.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.

From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival (OS)
Periodo de tiempo: Approximately 60 months (time from the date of randomization until the date of death due to any cause)

Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

Approximately 60 months (time from the date of randomization until the date of death due to any cause)
Objective Response Rate (ORR)
Periodo de tiempo: Approximately 32.8 months

ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.

Approximately 32.8 months
Duration of Response (DOR)
Periodo de tiempo: Approximately 32.8 months

DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.

Approximately 32.8 months
Progression-Free Survival After First Subsequent Therapy (PFS2)
Periodo de tiempo: Approximately 60 months

The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.

Approximately 60 months
Time to Symptomatic Progression (TTSP)
Periodo de tiempo: Approximately 60 months

TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.

Approximately 60 months
Intracranial PFS
Periodo de tiempo: Approximately 60 months

Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.

Approximately 60 months
Incidence and Severity of Adverse Events (AEs)
Periodo de tiempo: Approximately 60 months

Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.

Approximately 60 months
Number of Participants With Clinical Laboratory Abnormalities
Periodo de tiempo: Approximately 60 months

Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.

Approximately 60 months
Number of Participants With Vital Signs Abnormalities
Periodo de tiempo: Approximately 60 months

Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.

Approximately 60 months
Number of Participants With Physical Examination Abnormalities
Periodo de tiempo: Approximately 60 months

Number of participants with physical examination abnormalities will be reported.

Approximately 60 months
Serum Concentration of Amivantamab
Periodo de tiempo: Approximately 60 months

Serum samples will be analyzed to determine concentrations of Amivantamab.

Approximately 60 months
Plasma Concentration of Lazertinib
Periodo de tiempo: Approximately 60 months

Plasma samples will be analyzed to determine concentrations of Lazertinib.

Approximately 60 months
Number of Participants With Anti-Amivantamab Antibodies
Periodo de tiempo: Approximately 60 months

Number of participants with antibodies to amivantamab will be reported.

Approximately 60 months
Change From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)
Periodo de tiempo: Baseline up to approximately 60 months

The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.

Baseline up to approximately 60 months
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Periodo de tiempo: Baseline up to approximately 60 months

EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline up to approximately 60 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de septiembre de 2020

Finalización primaria (Actual)

11 de agosto de 2023

Finalización del estudio (Estimado)

16 de febrero de 2028

Fechas de registro del estudio

Enviado por primera vez

23 de julio de 2020

Primero enviado que cumplió con los criterios de control de calidad

23 de julio de 2020

Publicado por primera vez (Actual)

27 de julio de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR108856
  • 2020-000743-31 (Número EudraCT)
  • 73841937NSC3003 (Otro identificador: Janssen Research & Development, LLC)
  • 2023-506576-27-00 (Identificador de registro: EUCT number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir